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INTRODUCTION
For patients with locally advanced cervical cancer (LACC), the 
current guidelines recommend primary chemoradiotherapy 
(CRT) [1]. Therefore, pre-therapeutic staging has an important 
role in the management of patients with LACC. Assessment of 
the nodal involvement of para-aortic lymph nodes (PALN) is 
critical to determine the field of radiation therapy (RT). 
The value of pre-treatment surgical PALN assessment has 
been evaluated in previous studies; however, the survival 
benefit of surgical staging has not yet been determined. One 
randomized trial failed to show any benefit of surgical staging 
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[2]. This trial was stopped prematurely after an interim analysis 
owing to a significant reduction in survival for patients staged 
surgically. Conversely, surgical staging has been shown to 
improve survival compared to conventional radiological stag-
ing in three Gynecologic Oncology Group (GOG) trials (GOG 
85, GOG 120, and GOG 165) [3]. Recently, a Cochrane review 
concluded that the decision to offer pre-treatment surgical 
PALN assessment needs to be individualized in LACC [4].
In the era of positron emission tomography/computed 
tomography (PET/CT), the role of surgical staging should be 
re-evaluated. PET/CT is the most accurate imaging method 
for assessing extrapelvic disease in LACC [5]. Its high true-
positive rate for PALN metastasis suggests that surgical 
staging is unnecessary when uptake is noted in the para-
aortic area. However, the overall false-negative rate of PALN 
involvement is around 12%, most of which is attributable to 
non-detectable nodal disease [6]. As such, surgical staging is 
potentially beneficial for patients who test negative for PALN 
on PET/CT. Considering postoperative complications and the 
high cost of surgical staging, a comprehensive cost-effective 
analysis is required to clarify the best treatment strategy for 
patients with LACC [4,7].
We sought to create a model to evaluate the cost-effecti-
veness of nodal staging surgery followed by tailored CRT 
compared to pelvic CRT for the treatment of LACC when no 
uptake is found in PALN on PET/CT. 
MATERIALS AND METHODS
A modified Markov model was constructed using TreeAge 
Pro software (TreeAge Software Inc., Williamstown, MA, USA). 
The model evaluated two strategies for patients with stage 
IIB or higher disease that were scheduled to undergo CRT 
for curative intent when no uptake was recorded in PALN on 
PET/CT (Fig. 1). The strategies were (1) pelvic CRT in line with 
PET/CT results and (2) nodal staging surgery, followed by 
extended-field CRT if PALN metastasis was found and pelvic 
CRT otherwise. The Markov states were (1) active treatment; 
(2) completed primary treatment without complications; (3) 
completed primary treatment with acute complications; (4) 
completed primary treatment with late complications; and (5) 
death. The cycle length was 1 year, and the time horizon for 
the analysis was 5 years. 
Under strategy 1, all patients were assumed to receive whole 
pelvic external-beam radiation (WPRT), six cycles of platinum-
based chemotherapy, and additional vaginal cylinder 
brachytherapy regardless of PALN status. Under strategy 2, 
all patients were assumed to receive PALN dissection up to 
renal vessel level followed by definite CRT; if PALN metastasis 
was found following surgery, extended-field RT, six cycles of 
platinum-based chemotherapy, and additional brachytherapy 
would be performed; if no metastasis was found in the PALN, 
patients would undergo WPRT, six cycles of platinum-based 
chemotherapy, and brachytherapy. The baseline model was 
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Fig. 1. Schematic model. CRT, chemoradiotherapy; EFRT, extended-field radiation therapy; PALN, para-aortic lymph node; PET/CT, positron 
emission tomography/computed tomography.
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developed from a payer’s perspective. Costs included hospital 
and professional costs associated with surgery, CRT, treatment 
of toxicity, and complications. Institutional Review Board app-
roval was waived in this cost-effectiveness analysis due to using 
datasets open to the public.
1. Clinical estimates
All medical variables used in the decision trees and their 
origins are listed in Table 1. The baseline false-negative rate of 
PET/CT was set at 12% for patients with LACC [6]. 
2. Survival
Survival data were extracted from the literature. We catego-
rized three cohorts to estimate outcomes: cohort 1, patients 
who undergo pelvic CRT without PALN metastasis; cohort 2, 
patients who undergo pelvic CRT only, despite the presence 
of occult PALN metastasis (unstaged PALN metastasis); and 
cohort 3, patients who undergo extended-field CRT due to 
PALN metastasis (fully staged PALN metastasis). Strategy 1 
included the outcomes of cohorts 1 and 2, while strategy 2 
included the outcomes of cohorts 1 and 3. 
For patients receiving pelvic CRT in the setting of no PALN 
involvement, 5-year overall survival was estimated based 
on the published literature [8-11]. Survival for individuals 
with occult PALN metastasis treated with extended-field 
CRT (cohort 3) was similar to that for patients without PALN 
metastasis and whose disease was managed with pelvic CRT 
alone (cohort 1) [12,13]. As no survival data were available for 
patients who receive pelvic CRT only, despite the presence 
of PALN metastasis (cohort 2), this assumption was varied in 
the sensitivity analysis to correct for the uncertainty in the as-
sumption. Five-year overall survival for patients with unstaged 
PALN metastasis (cohort 2) was modeled at 45%, reflecting a 
30% reduction in survival compared to nodal staging surgery 
Table 1. Clinical estimates
Parameter Baseline estimate Range References
Utility Lesnock et al. (2013) [14]
    Radiation 0.76
    Recovery 0.86
    Acute GU 0.68
    Chronic GU 0.55
    Acute GI 0.62
    Chronic GI 0.63
    Survivor (after 1 year) 0.90 Ahn and Kim (2012) [21]
Probabilities Lesnock et al. (2013) [14]
    Acute GI toxicity/pelvic 0.08
    Acute GI toxicity/EFRT 0.15
    Chronic GI toxicity/pelvic 0.03
    Chronic GI toxicity/EFRT 0.12
    Acute GU toxicity/pelvic 0.02
    Acute GU toxicity/EFRT 0.02
    Chronic GU toxicity/pelvic 0.03
    Chronic GU toxicity/EFRT 0.03
False-negative rate for PALN metastasis, PET/CT 0.12 0.05–0.15 Gouy et al. (2013) [25]
Postoperative complication rate (lymphedema, lymphocele) 0.03 0–0.3 Gouy et al. (2013) [25]
5-Year overall survival 
    PALN metastasis, fully staged, followed by extended-field CRT 0.65 0.6–0.7 Leblanc et al. (2007) [12]
    PALN metastasis, unstaged, followed by pelvic CRT 0.45* 0.4–0.6 Assumption 
    No PALN metastasis, followed by pelvic CRT 0.65 0.6–0.7 Rose et al. (2007) [10]
CRT, chemoradiotherapy; EFRT, extended-field radiation therapy; GI, gastrointestinal; GU, genitourinary; PALN, paraaortic lymph node; PET/CT, 
positron emission tomography/computed tomography.
*Includes assumed 30% reduction in patients with unstaged PALN metastasis.
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followed by extended-field CRT in occult PALN metastasis 
(cohort 3). Considering the 12% baseline false-negative rate 
for PET/CT in detecting PALN metastasis, strategy 1 included 
88% of cohort 1 and 12% of cohort 2, and strategy 2 consisted 
of 88% of cohort 1 and 12% of cohort 3. Assuming that the 
survival rate in cohort 2 was 30% less than that in cohort 3, 
we could infer that the 5-year overall survival rate for patients 
in strategy 2 was approximately 2.4% higher than that of pa-
tients in strategy 1 in terms of baseline PET/CT performance.
3. Utilities 
Quality of life (QOL) adjustments are listed in Table 1. We also 
assumed same utility conditions as suggested in a previous 
study [14]. QOL during the treatment phase was estimated 
at 0.76 [15]. For the 3 months of recovery from radiotherapy 
(RT), utility was assumed to be 0.86 [16]. Loss in QOL from 
acute gastrointestinal (GI) complications was based on toxicity 
for grade 3 to 4 nausea/vomiting/anorexia and diarrhea or 
proctitis [17,18]. Acute genitourinary (GU) QOL was estimated 
based on the utility value for cystitis [19]. Patient QOL from 
chronic GI and GU toxicities was based on utilities for bowel 
obstruction and rectovaginal/vesicovaginal fistula [20]. Upon 
completion of active treatment, patients were assumed to 
return to a cervical cancer survivor utility score for Korea (0.898) 
unless they experienced late complications, in which case the 
appropriate utility score was then applied [21]. 
4. Toxicity
We assumed the same toxicity conditions as suggested 
in a previous study [14]. In this study, toxicity was based on 
conventional RT technology. Baseline probability estimates 
are shown in Table 1. Acute GI toxicities include nausea/
vomiting/anorexia and diarrhea or proctitis. Bowel obstruction 
was included as a chronic GI condition. Acute GU toxicities 
included cystitis, and chronic GU conditions were rectovaginal 
and vesicovaginal fistulas. 
5. Cost 
Costs were incorporated into the model using claims data 
from the Health Insurance Review and Assessment Service 
(Table 2). Amounts are expressed in US dollars; the exchange 
rate was 1,121.00 Korean won to one US dollar in July 2013. A 
payer perspective was used.
Costs excluding complications were investigated using 
microcosting, which calculates costs after listing the total re-
sources used and matching the unit cost of each component. 
Nodal staging surgery costs included fees for laparoscopic 
surgery, pathology, anesthesia, and 4 days of admission. Since 
intensity-modulated RT was not commonly used in Korea at 
that time, its associated cost was not included in this model. 
Chemotherapy costs were calculated for a hypothetical woman 
with a body surface area of 1.5 m2 and included the cost of 
administration, pre-medication, and the chemotherapeutic 
agent. The calculated dose for the chemotherapy regimen 
was cisplatin at 40 mg/m2. For complications, patient-level 
costs were collected and the average cost calculated. All 
patients were assumed to incur the cost of cancer treatment, 
excluding palliative care, when entering the first Markov cycle. 
Costs attributed to the final year of life were obtained from a 
retrospective assessment of Korean health-care costs attrib-
uted to the last year of life in patients with terminal cervical 
cancer [22]. 
6. Key assumptions
Key assumptions of our study are as follows: (1) all surgical 
staging is performed using an extraperitoneal laparoscopic 
approach, and nodal staging surgery is 100% sensitive and 
specific; (2) if PET/CT shows negative findings in PALN, occult 
nodal metastases (unstaged PALN) measure less than 5 mm at 
the time of surgical staging; and (3) definite CRT is performed 
within 4 weeks of nodal staging surgery and no damage 
Table 2. Costs incorporated into the model using claims data from 
the Health Insurance Review and Assessment Service
Parameter Costs ($)
Whole pelvic radiation therapy (total) 7,846
    Planning 498
    Treatment 6,251
    Intracavitary radiation 1,097
Extended-field radiation therapy (total) 8,577
    Planning 708
    Treatment 6,771
    Intracavitary radiation 1,097
Laparoscopic para-aortic lymphadenectomy 731
Weekly cisplatin, 6 cycles 1,421
Medical expenses in the last year of life 9,813
Postoperative complication (lymphocele, lymphedema) 1,913
Toxicities
    Nausea/vomiting 28
    Diarrhea 21
    Bowel obstruction 1,802
    Anorexia 55
    Proctitis 1,809
    Dysuria 43
    Vesicovaginal fistula 3,141
    Rectovaginal fistula 2,562
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results from a delay in starting curative treatment. In addition, 
we do not consider other postoperative complications, with the 
exception of lymphoceles and lymphedema, as the incidence 
of these complications is very low if a highly skilled surgeon 
performs the operation using an extraperitoneal approach.
7. Cost-effectiveness and sensitivity analysis
Effectiveness was calculated in quality-adjusted life years 
(QALY). Costs are discounted at 5% annually. The incremental 
cost-effectiveness ratio (ICER) is the ratio of the additional 
economic impact of a strategy relative to the improvement in 
QALY.
We conducted one-way sensitivity and probabilistic 
sensitivity analyses to evaluate the impact of a variation in 
parameters on the resulting ICER. One-way sensitivity analyses 
were carried out based on the performance of PET/CT (false-
Table 4. One-way sensitivity analyses of selected variables
Variable
Strategy 1 Strategy 2
ICER (US $/QALY)
Cost (US $) Effectiveness (QALYs) Cost (US $) Effectiveness (QALYs)
Survival reduction rate* (%)
    10 12,830 3.80 13,881 3.80 206,489
    13 12,850 3.79 13,881 3.80 92,113
    16 12,869 3.79 13,881 3.80 58,249
    19 12,888 3.78 13,881 3.80 42,018
    22 12,908 3.77 13,881 3.80 32,494
    25 12,927 3.77 13,881 3.80 26,232
    28 12,947 3.76 13,881 3.80 21,802
    31 12,967 3.75 13,881 3.80 18,503
    34 12,986 3.75 13,881 3.80 15,951
    37 13,005 3.74 13,881 3.80 13,918
    40 13,026 3.73 13,881 3.80 12,261
False negative rate of PET/CT to detect PALN metastasis (%)
    5 12,847 3.79 13,780 3.81 47,475
    7 12,879 3.78 13,809 3.81 33,775
    9 12,912 3.77 13,838 3.81 26,165
    11 12,944 3.76 13,866 3.80 21,321
    13 12,976 3.75 13,895 3.80 17,968
    15 13,009 3.74 13,924 3.80 15,509
Postoperative complication rate (%)
    0 12,960 3.76 13,672 3.80 15,070
    3 12,960 3.76 13,881 3.80 19,505
    6 12,960 3.76 14,090 3.80 23,939
    9 12,960 3.76 14,299 3.80 28,373
    12 12,960 3.76 14,509 3.80 32,807
    15 12,960 3.76 14,718 3.80 37,242
    18 12,960 3.76 14,927 3.80 41,676
    21 12,960 3.76 15,137 3.80 46,110
    24 12,960 3.76 15,346 3.80 50,544
    27 12,960 3.76 15,555 3.80 54,978
    30 12,960 3.76 15,765 3.80 59,412
ICER, incremental cost-effectiveness ratio; PALN, para-aortic lymph node; PET/CT, positron emission tomography/computed tomography; 
QALY, quality-adjusted life year.
*In patients with unstaged PALN metastasis.
Table 3. Cost-effectiveness analysis
　Variable Strategy 1 Strategy 2 Difference ICER
Effectiveness (QALY) 3.755 3.803 0.048 -
Total costs (US $) 12,960 13,881 921 19,505
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life 
year.
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negative rates), rates of postoperative complications, and 
survival reduction when pelvic CRT alone was performed 
for patients with unstaged PALN metastasis. To quantify the 
comprehensive effect of uncertainty, a probabilistic sensitivity 
analysis was tested using a Monte Carlo simulation.
RESULTS
1. Base case
In the base-case analysis, with a 12% false-negative rate of 
PET/CT detecting PALN metastasis, nodal staging surgery 
followed by tailored CRT resulted in an additional cost of $921 
per patient, with an increase in effectiveness of 0.048 QALYs. 
Compared to pelvic CRT alone, the ICER for nodal staging 
surgery was $19,505/QALY (Table 3).
2. Sensitivity analysis
One-way sensitivity analyses were performed on selected 
variables in the model across the ranges specified in Table 4. In 
the base-case model, a 30% reduction in survival is assumed 
if patients undergo pelvic CRT despite the presence of 
occult PALN metastasis. As the true effect of unstaged PALN 
metastasis is unknown in LACC, the percentage reduction 
in survival was varied for sensitivity analysis. The model was 
relatively sensitive to changes in survival reduction in patients 
who undergo pelvic CRT despite the presence of occult PALN 
metastasis (cohort 2) compared to those who had nodal 
staging surgery followed by tailored CRT as a result of PALN 
metastasis (cohort 3). When the reduction in survival was 
less than 17%, the ICER per QALY saved increases to $50,000, 
and when the reduction in survival was less than 12%, the 
ICER increased to $100,000 per QALY saved. The model was 
insensitive to changes in the performance of PET/CT and 
postoperative complication rates when rates were varied over 
clinically reasonable ranges. Nodal staging surgery followed 
by tailored CRT was more cost-effective than pelvic CRT alone, 
as the ICER did not exceed $50,000/QALY so long as the false-
negative rate for PET/CT is higher than 5%. If postoperative 
complication rates were below 30%, ICER did not exceed 
$60,000/QALY.
A probabilistic sensitivity analysis was conducted using 
a Monte Carlo simulation of 10,000 trials. The acceptability 
curve, depicted in Fig. 2, shows a comparison between the 
two strategies. Probabilistic sensitivity analysis demonstrates 
the robustness of the base-case results, with a 48%, 82%, and 
91% probability of cost-effectiveness at the willingness-to-
pay thresholds of $20,000/QALY, $40,000/QALY, and $60,000/
QALY, respectively.
DISCUSSION
To date, there is no absolute threshold of cost-effectiveness 
that policy-makers will consider for a strategy to be accept-
able. In the US, $50,000 per QALY is frequently cited as being 
cost-effective. The ICER threshold in South Korea has not been 
determined officially. The ‘World Health Report 2002’ suggests 
that an intervention that costs less than three times the gross 
domestic product (GDP) per capita for each disability-adjusted 
life year is cost-effective. As GDP per capita in South Korea in 
2011 was $21,539, a willingness-to-pay threshold of $60,000/
QALY (around three times the Korean GDP per capita) is used 
to define a cost-effective strategy from the standpoint of 
resource utilization in the Korean healthcare system [23,24]. 
In this study, a cost-effectiveness analysis was performed 
that compared two strategies LACC; the results showed that 
nodal staging surgery followed by tailored CRT is a cost-
effective treatment option within clinically acceptable range 
of variables. To date, no studies have evaluated the cost-
effectiveness of nodal staging surgery in the era of PET/CT.
A major limitation of our study is the lack of survival data for 
unstaged PALN metastasis in the model as no prospective trial 
has been performed that compares the outcomes of nodal 
staging followed by tailored CRT and pelvic CRT without 
surgical staging in the era of PET/CT. The base-case scenario 
assumes a 30% reduction in overall survival when patients un-
dergo pelvic CRT despite the presence of occult PALN metas-
tasis. Our model is clearly sensitive to changes in survival dif-
ferences between patients who undergo pelvic CRT and those 
with who have nodal staging surgery in cases with occult 
PALN metastasis. Nodal staging surgery followed by tailored 
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CRT is cost-effective (ICER <$60,000) when survival reduction 
falls within a clinically reasonable range. At the baseline false-
negative rate for PET/CT detecting PALN metastasis (12%), a 
15% reduction in the survival rate for patients with unstaged 
PALN metastasis indicates that the 5-year overall survival rate 
for strategy 2 is higher than for strategy 1 by approximately 
1.7%. Although no randomized trials evaluate the role of 
surgical staging in the era of PET/CT, prospective studies sug-
gest that nodal staging surgery followed by extended-field 
CRT provides survival gains for patients with PALN metastases 
measuring 5 mm or less metastases that would probably be 
missed by PET/CT [12,25].
Other one-way sensitivity analyses show the robustness of 
our cost-effectiveness results. The proportion of cases of PALN 
metastasis showing no uptake on PET or PET/CT but proven 
by histologic analysis to be positive (false-negative rate) was 
5% to 17%. Nodal staging surgery followed by tailored CRT is 
cost-effective for a wide range of false-negative rates for PET/
CT detecting PALN metastasis. Moreover, morbidity following 
surgical staging should be considered together with possible 
perioperative and late adverse effects. Although we consider 
only lymphocele and lymphedema, an extraperitoneal 
approach is shown to reduce perioperative morbidity and 
particularly the incidence of RT-induced complications [26]. 
The incidence rates for lymphocele and lymphedema that re-
quire intervention following nodal staging surgery are within 
tolerable range (less than 10%) when performed by highly 
skilled surgeons [25]. Our model shows that nodal staging 
surgery is cost-effective with a wide range of postoperative 
complication rates.
If PET/CT shows negative findings for PALN metastasis, we 
assume that any occult PALN metastases (unstaged PALN) 
measure less than 5 mm at the time of surgical staging. 
Some showed that the survival rate for patients with PALN 
metastases measuring 5 mm or less (when treated with nodal 
staging surgery followed by extended-field CRT) is similar 
to that of women without PALN metastasis [12]. However, 
a con siderable proportion of cases where PALN metastases 
measure more than 5 mm (6.8%) was found in a prospective 
trial despite negative uptake in PET/CT [25]. Gouy et al. [25] 
demonstrated that the event-free survival rate at 3 years in 
patients with PALN metastases measuring more than 5 mm 
was just 17%. For PALN involvement greater than 5 mm 
in particular, the survival gains from nodal staging surgery 
followed by extended-field CRT are not clear. Therefore, 
the survival outcome of nodal staging surgery followed by 
tailored CRT reported in this study may be overestimated.
Other limitations of this study include the assumption that 
there was no delay in the administration of definite CRT after 
nodal staging surgery. A major drawback of nodal staging 
surgery is the resultant delay in starting curative treatment, 
attributable to either an overburdened surgical schedule or 
postoperative morbidity [27].
Despite these limitations, our model provides an insight 
into how clinicians might approach treatment decisions for 
patients with LACC. Based on previous results, a considerable 
proportion of patients have PALN metastasis even when no 
uptake is found in PET/CT. Nodal staging surgery followed 
by extended-field CRT can be expected to improve survival 
outcomes in this subgroup without adding a significant 
economic burden. 
In conclusion, nodal staging surgery before CRT is potentially 
cost-effective in clinically acceptable ranges for LACC when 
PET/CT shows no evidence of PALN metastasis. While definite 
data are needed to confirm our results, this study demon-
strates the merit of incorporating nodal staging surgery in 
future prospective trials. This study opens up discussion of the 
possibility that nodal staging surgery may be cost-effective in 
the era of PET/CT. Prospective trials are warranted to transfer 
these results to guidelines.
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